QUADRIVALENT ANTI-HPV VACCINE: THE PREVENTION OF CANCER AND GENITAL CONDYLOMAS


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The paper reviews the data available in the literature on the primary prevention of cancer of the cervix uteri and other diseases associated with human papillomavirus (HPV). It gives update on clinical trials of a quadrivalent anti-HPV vaccine, covers its introduction in different countries, and shows the clinical and economic benefits of its use.

Texto integral

Acesso é fechado

Sobre autores

S. ROGOVSKAYA

Russian Medical Academy of Postgraduate Education

Email: srogovskaya@mail.ru

N. PODZOLKOVA

Russian Medical Academy of Postgraduate Education

Bibliografia

  1. Вакцины для профилактики рака шейки матки / Под ред. П.Л. Стерна, Г.С. Китченера: Пер. с англ.: Под ред. Г.Т. Сухих, В.Н. Прилепской. - М.: Медпресс, 2009.
  2. Женская консультация: Руководство / Под ред. В.Е. Радзинского. — М.: ГЭОТАР-Медиа, 2010.
  3. Минкина Г.Н., Манухин И.Б., Франк Г.А. Предрак шейки матки. - М.: Аэрограф-медиа, 2001.
  4. Роговская С.И. Папилломавирусная инфекция и патология шейки матки. - М.: ГЭОТАР-Медиа, 2009.
  5. Bosch Х., Gissman L., Kocken M. et al. European Consensus Statement on «HPV Vaccination and Colposcopy» Prepared on behalf of the European Federation for Colposcopy (EFC), May 2010 F.
  6. Brotherton J., Fridman M., Saville M., Gertig D. First indication of a possible impact on cervical abnormalities following a national HPV vaccination program, in Victoria, Australia // Abstracts of 26 HPV conference. - Montreal, 2010.
  7. Brown D.R. et al. HPV management // J. Infect. Dis. - 2009. -Vol. 199. - P. 926—35.
  8. Castellsague X. Prevalence incidence and persistence of genital HPV infection in women between the ages of 25 and 45 // Abstracts of 26 HPV conference. - Montreal, 2010.
  9. Dana A., Buchanan K., Goss M.A. et al. Updated data from the pregnancy registry for Gardasil // Abstracts of 25 HPV conference. - Sweeden, 2009.
  10. Daron F. End of study efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related persistent infection and disease in women aged 24 to 45 // Abstracts of 26 HPV conference. -Montreal, 2010.
  11. Dillner J. HPV Management // Abstracts of 25 HPV conference. -Sweeden, 2009.
  12. Dobson S., Dawar M., Kollmann T. et al. A two dose HPV vaccine schedule in girls: immunonogenicity at 24 months // Abstracts of 26 HPV conference. - Montreal, 2010.
  13. Donovan B., Franklin N., Guy R. et al. A national outcome for quadrivalent HPV vaccination: declining rates of genital warts in Australia // Abstracts of 26 HPV conference. - Montreal, 2010.
  14. Dunne E.F. et al. Strategies to monitor HPV vaccine impact in US // Abstracts of 25 HPV conference. - Sweeden, 2009.
  15. Garbe E., Schink T., Schulze-Rath R. et al. Incidence rates of anogenital warts in Germany // Аbstracts of 26 HPV conference. - Montreal, 2010.
  16. «Genital HPV Infection - CDC Actuality Sheet». Centers for Ache Ascendancy and Prevention (CDC). April 10, 2008. Global Advisory Committee on Vaccine Safety (GACVS) (2007).
  17. Giuliano A., Palefsky J. Quadrivalent HPV vaccine efficacy against ana HPV infection in men having sex with men // Abstracts of 26 HPV conference. - Montreal, 2010.
  18. Goldstone S. Incidence of genital warts among men in the placebo arm of a quadrivalent HPV vaccine trial // Abstracts of 26 HPV conference. - Montreal, 2010.
  19. Harper D.M. Currently approved prophylactic HPV vaccines // Expert Rev. Vaccines. - 2009. - Vol. 8, № 12. - P. 1663—1679.
  20. Hillman R., Jones R., Kumaradevan N. et al.The detection of HPV genotypes in anal cancer biopsy specimens from Sydney, Australia // Abstracts of 25 HPV conference. - Sweeden, 2009.
  21. Human papillomavirus vaccines: WHO position paper // Biologicals. - 2009. - Vol. 37, № 5. - P. 338—344.
  22. Irwin K.L., Hombach J., Aguado M.R. WНO recommendations: use of НPV vaccines in national immunization programmes // Abstracts of 26 HPV conference. - Montreal, 2010.
  23. Kjaer S. et al. Prueba de detección del VPH enel cribado rutinario de cáncer decuello de útero / Сancer Prev. Res. -2009. - Vol. 2. - P. 868.
  24. Koutsky L.A., Ault K.A., Wheeler C.M. et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine // N. Engl. J. Med. - 2002. - Vol. 347. -P. 1645-1651.
  25. Liaw K.L., Giuliano A., Hillman R. et al. // Garner incidence rates of detection of HPV 6, 11, 16, or 18 in a cohort of more than 2,000 young men in 14 countries // Abstracts of 26 HPV conference. - Montreal, 2010.
  26. Michels K.B., zur Hausen H. HPV vaccine for all // Lancet. - 2009. - Vol. 374, № 9686. - P. 268—270.
  27. Munoz N. et al. Cáncer de vulva // J. Natl. Cancer Inst. - 2010. - Vol. 102. - P. 325.
  28. Munos N., Manakatos R. et al. Safety, immunogenicity abd efficacy of quadrivalent HPV 6,11,16,18 recombinant vaccine in women age 24-45 years // Lancet. - 2009. - Vol. 373. -P. 1949—1953.
  29. Olsson S.O., Paavonen J. Impact of 6/11/16/18 vaccine on abnormal pap tests and procedures // Abstracts of 25 HPV conference. - Sweeden, 2009.
  30. Olsson S.E., Villa L.L., Costa R.L. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine // Vaccine. - 2007. - Vol. 25. - P. 49314939.
  31. Palefsky J. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men // Abstracts of 26 HPV conference. - Montreal, 2010.
  32. Rowhani-Rahbar A., Mao C., Hughes J.P. et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine // Vaccine. - 2009. - Vol. 27, № 41. - Р. 5612— 5619.
  33. Schiller J.T. et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results // Vaccine. - 2008. - Vol. 26. - Suppl. 10. - P. 53-62.
  34. Sexually transmitted infections quarterly report: Anogenital warts and HSV infection in England and Wales // CDR Wkly. - 2001. - Vol. 11, № 35.
  35. Stanley M. Prospects for new human papillomavirus vaccines // Curr. Opin. Infect. Dis. - 2009.
  36. Syrjänen K.J. Prophylactic HPV vaccines: the Finnish perspective // Expert Rev. Vaccines. - 2010. - Vol. 9, № 1. -Р. 45—50.
  37. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions // N. Engl. J. Med. - 2007. - Vol. 356. - P. 1915-1927.
  38. Villa L.L., Costa R.L., Petta C.A., et al. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) types 6, 11, 16 and 18 L1 virus-like particle vaccine through up to 5 years of follow-up // Br. J. Cancer. - 2006. - Vol. 95. - P. 1459-1466.
  39. Villa L.L., Costa R.L., Petta C.A et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial // Lancet Oncol. - 2005. - Vol. 6. - P. 271—278.
  40. www.who.hpv-center.com

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2011

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies